TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study-Reference-Cited by-同舟云学术

TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study

Published:2018-04-15 Issue:2 Volume:50 Page:398-404
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Bang Yung-Jue,Takano Toshimi,Lin Chia-Chi,Fasanmade Adedigbo,Yang Huyuan,Danaee Hadi,Asato Takayuki,Kalebic Thea,Wang Hui,Doi Toshihiko

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://www.e-crt.org/upload/pdf/crt-2017-074.pdf

Reference31 articles.

1. Antibody Conjugate Therapeutics: Challenges and Potential

2. Site-specific antibody drug conjugates for cancer therapy

3. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

4. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer

5. Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies;Gastric Cancer;2024-07-04

2. Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature;Frontiers in Oncology;2023-10-20

3. Mixed data analysis detected Endocrine Fibroblast Growth Factors (FGF19, FGF21, and FGF23) as Prognostic and Diagnostic Markers of Colorectal Neoplasia and Carcinoma;2023-06-29

4. A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C;Cancer Chemotherapy and Pharmacology;2023-02-04

5. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential;Pharmacology & Therapeutics;2022-08